[Does para-cervical block offer additional advantages in abortion induction with gemeprost in the 2nd trimester?].
Uterus-specific synthetic Prostaglandin analogues (gemeprost, sulproston etc.) have been widely employed for termination of pregnancy in the second trimester. Since paracervical anaesthesia may be useful during this procedure, we investigated in this prospective randomised study its impact on the clinical course of abortion and pain especially in the late first and second stage of labour.


METHODS
20 women scheduled for elective abortion (fetal reasons) between the 16th and 23rd week of gestation were to be given 1 mg gemeprost vaginally every 6 hours. They were allocated at random: 10 women received only Pethidin intravenously and Butylscopolamine rectally, another 10 women were additionally treated by paracervical anaesthesia (2 x 10 ml 0.5% Bupivacain solution) at a cervical dilatation of 2-3 cm.


RESULTS
A median of 3 gemeprost applications were administered in both groups. In the group without paracervical anaesthesia the median induction to abortion interval was 20 hours (range: 8-44 hours), 13 hours (range: 8-36 hours, NS) resulting for the paracervical anaesthesia group. The intervals from the last application of prostaglandin until abortion and from 3 cm cervical dilatation to abortion were slightly, but not significantly shorter in the paracervical anaesthesia group. The requirement of Butylscopolamine was higher in the latter group (p < 0.05). The requirement of Pethidin and the intensity of pain (measured by pain scale according to Huskisson) especially in the late first stage of labour were not statistically different between both groups. Side effects of paracervical anaesthesia did not occur.


CONCLUSIONS
Paracervical anaesthesia is a method for analgesia during second trimester abortion with a low rate of side effects. It can shorten the duration of last period of second trimester abortion in some cases but has no impact on the perception of pain nor requirement of analgesics and so with only limited benefit in second trimester abortion with vaginal gemeprost.
Winkler
M
M
Frauenklinik, Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule (RWTH) Aachen.
Wolters
S
S
Funk
A
A
Rath
W
W
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage*; D000025:Abortion, Eugenic; D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000772:Anesthesia, Local; D000773:Anesthesia, Obstetrical; D002045:Bupivacaine; D002584:Cervix Uteri / Q000187:drug effects; D005260:Female; D006801:Humans; D010147:Pain Measurement; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D011446:Prospective Studies
D000020:Abortifacient Agents, Nonsteroidal; C021182:gemeprost; D000527:Alprostadil; D002045:Bupivacaine
Bietet die Parazervikalblockade zusätzliche Vorteile bei der Abortinduktion mit Gemeprost im II. Trimenon?